{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:09:09Z","timestamp":1794834549413,"version":"4.9.1"},"reference-count":262,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04115-1","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T17:21:01Z","timestamp":1744824061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Sunil","family":"Bhandari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Mikhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owain","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Willicombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Baines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Alldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Haslam-England","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"4115_CR1","unstructured":"UK Renal Registry. UK Renal Registry 25th Annual Report \u2013 data to 31\/12\/2021. Bristol: UK Renal Registry. 2023. Available from: https:\/\/ukkidney.org\/audit-research\/annual-report. Accessed 1st December 2024."},{"key":"4115_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"4115_CR3","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/sj.ki.5001875","volume":"70","author":"K Uhlig","year":"2006","unstructured":"Uhlig K, MacLeod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. Kidney Int. 2006;70:2058\u201365.","journal-title":"Kidney Int"},{"issue":"1","key":"4115_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12882-017-0688-1","volume":"18","author":"A Mikhail","year":"2017","unstructured":"Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, Isaac H, Bhandari S. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 2017;18(1):345.","journal-title":"BMC Nephrol"},{"key":"4115_CR5","unstructured":"National Collaborating Centre for Chronic Conditions, Royal College of Physicians. Chronic kidney disease assessment and management. London: National Institute for Clinical Excellence. 2015 (last updated November 2021). Available from: http:\/\/www.nice.org.uk\/guidance\/NG203. Accessed 1st December 2024."},{"key":"4115_CR6","first-page":"429","volume":"28","author":"A Besarab","year":"2001","unstructured":"Besarab A, Dalton CL. Maintaining higher TSATs and other iron indices is beneficial in management of anaemic haemodialysis patients. Nephrol Nurs J. 2001;28:429\u201334.","journal-title":"Nephrol Nurs J"},{"key":"4115_CR7","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1097\/01.ASN.0000013294.11876.80","volume":"13","author":"JA Coladonato","year":"2002","unstructured":"Coladonato JA, Frankenfield DL, Reddan DN, et al. Trends in anaemia management among US haemodialysis patients. J Am Soc Nephrol. 2002;13:1288\u201395.","journal-title":"J Am Soc Nephrol"},{"key":"4115_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0272-6386(03)00915-6","volume":"42","author":"K Kalantar-Zadeh","year":"2003","unstructured":"Kalantar-Zadeh K, McAllister CJ, Lehn RS, et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance haemodialysis patients. Am J Kidney Dis. 2003;42:761\u201373.","journal-title":"Am J Kidney Dis"},{"key":"4115_CR9","doi-asserted-by":"publisher","first-page":"E36","DOI":"10.1016\/S0272-6386(05)90000-0","volume":"37","author":"WM McClellan","year":"2001","unstructured":"McClellan WM, Frankenfield DL, Wish JB, et al. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult haemodialysis patients: results from the 1998 End-Stage renal disease core indicators project. Am J Kidney Dis. 2001;37:E36.","journal-title":"Am J Kidney Dis"},{"key":"4115_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1053\/ajkd.2001.25203","volume":"38","author":"D Richardson","year":"2001","unstructured":"Richardson D, Bartlett C, Will EJ. Optimizing erythropoietin therapy in haemodialysis patients. Am J Kidney Dis. 2001;38:109\u201317.","journal-title":"Am J Kidney Dis"},{"key":"4115_CR11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1681\/ASN.V113530","volume":"11","author":"A Besarab","year":"2000","unstructured":"Besarab A, Amin N, Ahsan M, et al. Optimization of Epoetin therapy with intravenous iron therapy in haemodialysis patients. J Am Soc Nephrol. 2000;11:530\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4115_CR12","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1053\/j.ajkd.2006.02.180","volume":"47","author":"YC Chen","year":"2006","unstructured":"Chen YC, Hung SC, Tarng DC. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in haemodialysis patients. Am J Kidney Dis. 2006;47(6):1036\u201344.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"4115_CR13","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1046\/j.1523-1755.2001.00077.x","volume":"60","author":"S Fishbane","year":"2001","unstructured":"Fishbane S, Shapiro W, Dutka P, et al. A randomized trial of iron deficiency testing strategies in haemodialysis patients. Kidney Int. 2001;60(6):2406\u201311.","journal-title":"Kidney Int"},{"issue":"1","key":"4115_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/ki.1997.323","volume":"52","author":"S Fishbane","year":"1997","unstructured":"Fishbane S, Galgano C, Langley RC Jr, et al. Reticulocyte haemoglobin content in the evaluation of iron status of haemodialysis patients. Kidney Int. 1997;52(1):217\u201322.","journal-title":"Kidney Int"},{"issue":"7","key":"4115_CR15","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/ndt\/16.7.1416","volume":"16","author":"N Tessitore","year":"2001","unstructured":"Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transpl. 2001;16(7):1416\u201323.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"4115_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s12288-021-01464-3","volume":"38","author":"P Karunarathne","year":"2022","unstructured":"Karunarathne P, Kulathilake C, Wijesiriwardena I, Hewageegana A, Marasinghe A. Evaluation of iron status by reticulocyte haemoglobin content (Chr) in chronic kidney disease patients on haemodialysis and erythropoietin. Indian J Hematol Blood Transfus. 2022;38(2):359\u201365. https:\/\/doi.org\/10.1007\/s12288-021-01464-3.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"6","key":"4115_CR17","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.mayocp.2020.10.042","volume":"96","author":"M Auerbach","year":"2021","unstructured":"Auerbach M, Staffa SJ, Brugnara C. Using reticulocyte hemoglobin equivalent as a marker for iron deficiency and responsiveness to iron therapy. Mayo Clin Proc. 2021;96(6):1510\u20139. https:\/\/doi.org\/10.1016\/j.mayocp.2020.10.042.","journal-title":"Mayo Clin Proc"},{"key":"4115_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/ijlh.12496","volume":"38","author":"E Urrechaga","year":"2016","unstructured":"Urrechaga E, Boveda O, Aguayo FJ, de la Hera P, Mu\u00f1oz RI, Gallardo I, Escanero JF. Percentage of hypochromic erythrocytes and reticulocyte hemoglobin equivalent predictors of response to intravenous iron in Hemodialysis patients. Int J Lab Hematol. 2016;38:360\u20135. https:\/\/doi.org\/10.1111\/ijlh.12496.","journal-title":"Int J Lab Hematol"},{"key":"4115_CR19","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1053\/j.ajkd.2006.03.020","volume":"47","author":"National Kidney Foundation","year":"2006","unstructured":"National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anaemia in chronic kidney disease. Section III. clinical practice recommendations for anaemia in chronic kidney disease in children. Am J Kidney Dis. 2006;47:S86\u2013108.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"4115_CR20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","volume":"6","author":"DW Coyne","year":"2020","unstructured":"Coyne DW, Roger SD, Shin SK, et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep. 2020;6(3):624\u201335.","journal-title":"Kidney Int Rep"},{"key":"4115_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1681\/ASN.2020081150","volume":"32","author":"S Fishbane","year":"2021","unstructured":"Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. J Am Soc Nephrol. 2021;32:737\u201355.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"4115_CR22","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","volume":"36","author":"E Shutov","year":"2021","unstructured":"Shutov E, Sulowicz W, Esposito C. Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS) [e-pub ahead of print]. Nephrol Dial Transpl. 2021;36(9):1629\u201339.","journal-title":"Nephrol Dial Transpl"},{"key":"4115_CR23","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","volume":"36","author":"J Barratt","year":"2021","unstructured":"Barratt J, Andric B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transpl. 2021;36:1616\u201328.","journal-title":"Nephrol Dial Transpl"},{"key":"4115_CR24","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","volume":"38","author":"B Csiky","year":"2021","unstructured":"Csiky B, Schomig M, Esposito C, et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Adv Ther. 2021;38:5361\u201373.","journal-title":"Adv Ther"},{"key":"4115_CR25","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/1744-9987.13468","volume":"24","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Ueno M, Shiga T, et al. Oral Roxadustat three times weekly in ESA-naive and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: results from two phase 3 studies. Ther Apher Dial. 2020;24:628\u201341.","journal-title":"Ther Apher Dial"},{"issue":"13","key":"4115_CR26","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.3390\/jcm12134217","volume":"12","author":"T Ganz","year":"2023","unstructured":"Ganz T, Locatelli F, Arici M, Akizawa T, Reusch M. Iron parameters in patients treated with Roxadustat for anemia of chronic kidney disease. J Clin Med. 2023;12(13):4217.","journal-title":"J Clin Med"},{"key":"4115_CR27","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/ndt\/gfab050","volume":"36","author":"M Guedes","year":"2021","unstructured":"Guedes M, Muenz D, Zee J, et al. Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia. Nephrol Dial Transpl. 2021;36:1694\u2013703.","journal-title":"Nephrol Dial Transpl"},{"key":"4115_CR28","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1681\/ASN.2020101531","volume":"32","author":"M Guedes","year":"2021","unstructured":"Guedes M, Muenz DG, Zee J, et al. Serum biomarkers of iron stores are associated with increased risk of all-cause mortality and cardiovascular events in nondialysis CKD patients, with or without anemia. J Am Soc Nephrol. 2021;32:2020\u201330.","journal-title":"J Am Soc Nephrol"},{"key":"4115_CR29","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1111\/j.1523-1755.2005.00758.x","volume":"68","author":"DB Van Wyck","year":"2005","unstructured":"Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anaemic patients with non-dialysis dependent CKD. Kidney Int. 2005;68:2846\u201356.","journal-title":"Kidney Int"},{"key":"4115_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1081\/JDI-120005364","volume":"24","author":"S Anuradha","year":"2002","unstructured":"Anuradha S, Singh NP, Agarwal SK. Total dose infusion iron dextran therapy in pre-dialysis chronic renal failure patients. Ren Fail. 2002;24:307\u201313.","journal-title":"Ren Fail"},{"key":"4115_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0272-6386(96)90546-6","volume":"27","author":"DS Silverberg","year":"1996","unstructured":"Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anaemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27:234\u20138.","journal-title":"Am J Kidney Dis"},{"key":"4115_CR32","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/ndt\/16.5.967","volume":"16","author":"J Stoves","year":"2001","unstructured":"Stoves J, Inglis H, Newstead CG. A randomized study of oral vs. intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transpl. 2001;16:967\u201374.","journal-title":"Nephrol Dial Transpl"},{"key":"4115_CR33","doi-asserted-by":"publisher","first-page":"c55","DOI":"10.1159\/000085049","volume":"100","author":"C Charytan","year":"2005","unstructured":"Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anaemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100:c55\u201362.","journal-title":"Nephron Clin Pract"},{"key":"4115_CR34","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/pharmaceutics14071408","volume":"14","author":"G Rostoker","year":"2022","unstructured":"Rostoker G, Lepeytre F, Merzoug M, et al. Differential pharmacokinetics of liver tropism for Iron sucrose, ferric carboxymaltose, and Iron isomaltoside: A clue to their safety for Dialysis patients. Pharmaceutics. 2022;14:1408. https:\/\/doi.org\/10.3390\/pharmaceutics14071408.","journal-title":"Pharmaceutics"},{"key":"4115_CR35","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.3390\/jcm11185284","volume":"11","author":"A Rosati","year":"2022","unstructured":"Rosati A, Conti P, Berto P, on behalf of the Tuscany Study Group for Ferric Carboxymaltose, et al. Efficacy, safety and Pharmacoeconomic analysis of intravenous ferric carboxymaltose in anemic Hemodialysis patients unresponsive to ferric gluconate treatment: A multicenter retrospective study. J Clin Med. 2022;11:5284. https:\/\/doi.org\/10.3390\/jcm11185284.","journal-title":"J Clin Med"},{"issue":"2","key":"4115_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4212\/cjhp.3310","volume":"76","author":"E England","year":"2023","unstructured":"England E, Sheffield M, Poyah P, Clark D, Wilson J-A. Ferric derisomaltose evaluation in patients with non\u2013dialysis-dependent chronic kidney disease or peritoneal dialysis. Can J Hosp Pharm. 2023;76(2):94\u2013101. https:\/\/doi.org\/10.4212\/cjhp.3310.","journal-title":"Can J Hosp Pharm"},{"key":"4115_CR37","first-page":"80","volume":"16","author":"N Ahsan","year":"2000","unstructured":"Ahsan N. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial. Adv Perit Dial. 2000;16:80\u20134.","journal-title":"Adv Perit Dial"},{"issue":"1","key":"4115_CR38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/ckj\/sfz153","volume":"14","author":"J Portol\u00e9s-P\u00e9rez","year":"2019","unstructured":"Portol\u00e9s-P\u00e9rez J, Dur\u00e1-G\u00farpide B, Merino-Rivas JL, Mart\u00edn-Rodriguez L, Hevia-Ojanguren C, Burguera-Vion V, et al. Effectiveness and safety of ferric carboxymaltose therapy in peritoneal dialysis patients: an observational study. Clin Kidney J. 2019;14(1):174\u201380.","journal-title":"Clin Kidney J"},{"issue":"4","key":"4115_CR39","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.numecd.2020.12.018","volume":"31","author":"D Luo","year":"2021","unstructured":"Luo D, Zhong Z, Qiu Y, Wang Y, Li H, Lin J, et al. Abnormal iron status is associated with an increased risk of mortality in patients on peritoneal dialysis. Nutr Metab Cardiovasc Dis. 2021;31(4):1148\u201355. https:\/\/doi.org\/10.1016\/j.numecd.2020.12.018.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"4","key":"4115_CR40","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/ki.2015.163","volume":"88","author":"R Agarwal","year":"2015","unstructured":"Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015;88(4):905\u201314.","journal-title":"Kidney Int"},{"key":"4115_CR41","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall IC, Bock AH, Carrera F, FIND-CKD Study Investigators, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transpl. 2014;29:2075\u201384.","journal-title":"Nephrol Dial Transpl"},{"key":"4115_CR42","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/ndt\/gfv293","volume":"31","author":"PA Kalra","year":"2016","unstructured":"Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transpl. 2016;31:646\u201355.","journal-title":"Nephrol Dial Transpl"},{"key":"4115_CR43","doi-asserted-by":"publisher","unstructured":"Bhandari S, Kalra PA, Kothari J, et al. Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant. 2021;36(1):111\u201320. https:\/\/doi.org\/10.1093\/ndt\/gfaa011(2020).","DOI":"10.1093\/ndt\/gfaa011("},{"key":"4115_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0272-6386(99)70103-4","volume":"34","author":"A Besarab","year":"1999","unstructured":"Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in haemodialysis patients. Am J Kidney Dis. 1999;34:21\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 2","key":"4115_CR45","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1053\/ajkd.1999.v34.aajkd0344b0040","volume":"34","author":"IC Macdougall","year":"1999","unstructured":"Macdougall IC, Chandler G, Elston O, et al. Beneficial effects of adopting an aggressive intravenous iron policy in a haemodialysis unit. Am J Kidney Dis. 1999;34(Suppl 2):S40\u20136.","journal-title":"Am J Kidney Dis"},{"key":"4115_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0272-6386(95)90151-5","volume":"26","author":"S Fishbane","year":"1995","unstructured":"Fishbane S, Frei GL, Maesaka J. Reduction in Recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41\u20136.","journal-title":"Am J Kidney Dis"},{"key":"4115_CR47","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/ki.1996.487","volume":"50","author":"IC Macdougall","year":"1996","unstructured":"Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694\u20139.","journal-title":"Kidney Int"},{"key":"4115_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ndt\/gfv096","volume":"0","author":"S Bhandari","year":"2015","unstructured":"Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer\u00ae) compared with iron sucrose (Venofer\u00ae) as maintenance therapy in haemodialysis patients. Nephrol Dial Transpl. 2015;0:1\u201313. https:\/\/doi.org\/10.1093\/ndt\/gfv096.","journal-title":"Nephrol Dial Transpl"},{"key":"4115_CR49","doi-asserted-by":"crossref","unstructured":"Macdougall IC, Bircher AJ, Eckardt KU, et al. Conference Participants. Iron management in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2016;89(1):28\u201339.","DOI":"10.1016\/j.kint.2015.10.002"},{"issue":"3","key":"4115_CR50","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/j.1523-1755.2004.00480.x","volume":"65","author":"C Canavese","year":"2004","unstructured":"Canavese C, Bergamo D, Ciccone G, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004;65(3):1091\u20138.","journal-title":"Kidney Int"},{"issue":"1","key":"4115_CR51","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1600-0609.2012.01783.x","volume":"89","author":"H Ghoti","year":"2012","unstructured":"Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term haemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012;89(1):87\u201393.","journal-title":"Eur J Haematol"},{"issue":"5","key":"4115_CR52","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","volume":"380","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, White C, Anker S, et al. Intravenous iron in patients undergoing maintenance haemodialysis. N Engl J Med. 2019;380(5):447\u201358.","journal-title":"N Engl J Med"},{"issue":"25","key":"4115_CR53","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436\u201348.","journal-title":"N Engl J Med"},{"issue":"11","key":"4115_CR54","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657\u201368.","journal-title":"Eur Heart J"},{"issue":"10369","key":"4115_CR55","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2022","unstructured":"Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10369):2199\u2013209.","journal-title":"Lancet"},{"issue":"1","key":"4115_CR56","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12882-021-02308-y","volume":"22","author":"S Bhandari","year":"2021","unstructured":"Bhandari S, Allgar V, Lamplugh A, Macdougall I, Kalra PA. A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric derisomaltose (FDI)) in iron deficient but not anaemic patients with chronic kidney disease on functional status. BMC Nephrol. 2021;22(1):115.","journal-title":"BMC Nephrol"},{"key":"4115_CR57","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.ekir.2023.05.002","volume":"8","author":"SA Greenwood","year":"2023","unstructured":"Greenwood SA, Oliveira BA, Asgari E, Ayis S, Baker LA, Beckley-Hoelscher N, et al. A randomized trial of intravenous iron supplementation and exercise on exercise capacity in iron-deficient nonanemic patients with CKD. Kidney Int Rep. 2023;8:1496\u2013505.","journal-title":"Kidney Int Rep"},{"key":"4115_CR58","doi-asserted-by":"publisher","first-page":"e019240","DOI":"10.1136\/bmjopen-2017-019240","volume":"8","author":"BL Houston","year":"2018","unstructured":"Houston BL, Hurrie D, Graham J, et al. Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults: a systematic review of randomised controlled trials. BMJ Open. 2018;8:e019240.","journal-title":"BMJ Open"},{"key":"4115_CR59","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.12659\/MSM.900520","volume":"23","author":"Y Deng","year":"2017","unstructured":"Deng Y, Wu J, Jia Q. Efficacy of intravenous iron sucrose in Hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo-controlled study. Med Sci Monit. 2017;23:1254\u201360.","journal-title":"Med Sci Monit"},{"issue":"4","key":"4115_CR60","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1053\/j.ajkd.2003.11.021","volume":"43","author":"JA Sloand","year":"2004","unstructured":"Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis. 2004;43(4):663\u201370.","journal-title":"Am J Kidney Dis"},{"key":"4115_CR61","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejim.2019.02.009","volume":"63","author":"T Avni","year":"2019","unstructured":"Avni T, Reich S, Lev N, et al. Iron supplementation for restless legs syndrome\u2014a systematic review and meta-analysis. Eur J Intern Med. 2019;63:34\u201341.","journal-title":"Eur J Intern Med"},{"key":"4115_CR62","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1046\/j.1523-1755.2003.00099.x","volume":"64","author":"G Weiss","year":"2003","unstructured":"Weiss G, Meusburger E, Radacher G, et al. Effect of iron treatment on Circulating cytokine levels in ESRD patients receiving Recombinant human erythropoietin. Kidney Int. 2003;64:572\u20138.","journal-title":"Kidney Int"},{"key":"4115_CR63","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/ndt\/gfq483","volume":"26","author":"T Sonnweber","year":"2011","unstructured":"Sonnweber T, Theurl I, Seifert M, et al. Impact of iron treatment on immune effector function and cellular iron status of Circulating monocytes in dialysis patients. Nephrol Dial Transpl. 2011;26:977\u201387.","journal-title":"Nephrol Dial Transpl"},{"key":"4115_CR64","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1111\/j.1462-5822.2010.01529.x","volume":"12","author":"M Nairz","year":"2010","unstructured":"Nairz M, Schroll A, Sonnweber T, Weiss G. The struggle for iron\u2014a metal at the host-pathogen interface. Cell Microbiol. 2010;12:1691\u2013702.","journal-title":"Cell Microbiol"},{"key":"4115_CR65","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.coi.2009.01.011","volume":"21","author":"T Ganz","year":"2009","unstructured":"Ganz T. Iron in innate immunity: starve the invaders. Curr Opin Immunol. 2009;21:63\u20137.","journal-title":"Curr Opin Immunol"},{"key":"4115_CR66","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1093\/ndt\/gft524","volume":"29","author":"LH Fell","year":"2014","unstructured":"Fell LH, Zawada AM, Rogacev KS, et al. Distinct Immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transpl. 2014;29:809\u201322.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"4115_CR67","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/sdi.12168","volume":"27","author":"JH Ishida","year":"2014","unstructured":"Ishida JH, Johansen KL. Iron and infection in haemodialysis patients. Semin Dial. 2014;27(1):26\u201336.","journal-title":"Semin Dial"},{"issue":"7","key":"4115_CR68","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1681\/ASN.2012121164","volume":"24","author":"MA Brookhart","year":"2013","unstructured":"Brookhart MA, Freburger JK, Ellis AR, et al. Infection risk with bolus versus maintenance iron supplementation in haemodialysis patients. J Am Soc Nephrol. 2013;24(7):1151\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4115_CR69","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/ki.2014.114","volume":"86","author":"T Kuragano","year":"2014","unstructured":"Kuragano T, Matsumura O, Matsuda A, et al. Association between hemoglobin variability, serum ferritin levels, and adverse events\/mortality in maintenance Hemodialysis patients. Kidney Int. 2014;86(4):845\u201354.","journal-title":"Kidney Int"},{"issue":"3","key":"4115_CR70","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1681\/ASN.V133734","volume":"13","author":"HI Feldman","year":"2002","unstructured":"Feldman HI, Santanna J, Guo W, et al. Iron administration and clinical outcomes in haemodialysis patients. J Am Soc Nephrol. 2002;13(3):734\u201344.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4115_CR71","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1097\/01.ASN.0000128009.69594.BE","volume":"15","author":"HI Feldman","year":"2004","unstructured":"Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among haemodialysis patients. J Am Soc Nephrol. 2004;15(6):1623\u201332.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"4115_CR72","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1681\/ASN.2005040423","volume":"16","author":"K Kalantar-Zadeh","year":"2005","unstructured":"Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in haemodialysis patients. J Am Soc Nephrol. 2005;16(10):3070\u201380.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"4115_CR73","doi-asserted-by":"publisher","first-page":"e78930","DOI":"10.1371\/journal.pone.0078930","volume":"8","author":"AV Kshirsagar","year":"2013","unstructured":"Kshirsagar AV, Freburger JK, Ellis AR, et al. Intravenous iron supplementation practices and short-term risk of cardiovascular events in haemodialysis patients. PLoS ONE. 2013;8(11):e78930.","journal-title":"PLoS ONE"},{"key":"4115_CR74","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1681\/ASN.V95869","volume":"9","author":"B Hoen","year":"1998","unstructured":"Hoen B, Paul-Dauphin A, Hestin D, et al. EPIBACDIAL: a multicentre prospective study of risk factors for bacteraemia in chronic haemodialysis patients. J Am Soc Nephrol. 1998;9:869\u201376.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4115_CR75","doi-asserted-by":"publisher","first-page":"457","DOI":"10.5414\/CNP57457","volume":"57","author":"B Hoen","year":"2002","unstructured":"Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteraemia in chronic haemodialysis patients. Clin Nephrol. 2002;57(6):457\u201361.","journal-title":"Clin Nephrol"},{"issue":"5","key":"4115_CR76","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1681\/ASN.2019090972","volume":"31","author":"IC Macdougall","year":"2020","unstructured":"Macdougall IC, Bhandari S, White C, et al. Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the PIVOTAL trial. J Am Soc Nephrol. 2020;31(5):1118\u201327. https:\/\/doi.org\/10.1681\/ASN.2019090972.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4115_CR77","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2215\/CJN.05390517","volume":"13","author":"I Hougen","year":"2018","unstructured":"Hougen I, Collister D, Bourrier M, et al. Safety of intravenous iron in dialysis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2018;13(3):457\u201367.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"4115_CR78","doi-asserted-by":"publisher","first-page":"e2133935","DOI":"10.1001\/jamanetworkopen.2021.33935","volume":"4","author":"AA Shah","year":"2021","unstructured":"Shah AA, Donovan K, Seeley C, et al. Risk of infection associated with administration of intravenous iron: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(11):e2133935. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.33935.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"4115_CR79","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","volume":"99","author":"D Rampton","year":"2014","unstructured":"Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671\u20136.","journal-title":"Haematologica"},{"key":"4115_CR80","first-page":"224","volume":"72","author":"HS Novey","year":"1994","unstructured":"Novey HS, Pahl M, Haydik I, et al. Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy. 1994;72:224\u20138.","journal-title":"Ann Allergy"},{"key":"4115_CR81","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1001\/jama.1980.03300430028018","volume":"243","author":"RD Hamstra","year":"1980","unstructured":"Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980;243:1726\u201331.","journal-title":"JAMA"},{"key":"4115_CR82","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0272-6386(96)90463-1","volume":"28","author":"S Fishbane","year":"1996","unstructured":"Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in haemodialysis patients. Am J Kidney Dis. 1996;28:529\u201334.","journal-title":"Am J Kidney Dis"},{"key":"4115_CR83","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1111\/j.1523-1755.2004.00648.x","volume":"65","author":"R Agarwal","year":"2004","unstructured":"Agarwal R, Vasavada N, Sachs NG, et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004;65:2279\u201389.","journal-title":"Kidney Int"},{"issue":"5","key":"4115_CR84","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1046\/j.1523-1755.2002.00314.x","volume":"61","author":"B Michael","year":"2002","unstructured":"Michael B, Coyne DW, Fishbane S, et al. Ferrlecit publication committee. Sodium ferric gluconate complex in haemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61(5):1830\u20139.","journal-title":"Kidney Int"},{"issue":"5","key":"4115_CR85","doi-asserted-by":"publisher","first-page":"656","DOI":"10.7326\/M21-4009","volume":"175","author":"CV Dave","year":"2022","unstructured":"Dave CV, Brittenham GM, Carson JL, Setoguchi S. Risks for anaphylaxis with intravenous iron formulations: a retrospective cohort study. Ann Intern Med. 2022;175(5):656\u201364.","journal-title":"Ann Intern Med"},{"issue":"10369","key":"4115_CR86","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2022","unstructured":"Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10369):2199\u2013209.","journal-title":"Lancet"},{"key":"4115_CR87","unstructured":"MHRA Drug Safety Update. (2013). Intravenous iron and serious hypersensitivity reactions: strengthened recommendations. Available from: https:\/\/www.gov.uk\/drug-safety-update\/intravenous-iron-and-serioushypersensitivity-reactions-strengthened-recommendations. Accessed 1st December 2024."},{"issue":"1","key":"4115_CR88","doi-asserted-by":"publisher","first-page":"8877","DOI":"10.1038\/s41598-019-45335-4","volume":"9","author":"K Yokoyama","year":"2019","unstructured":"Yokoyama K, Fukagawa M, Akiba T, et al. Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. Sci Rep. 2019;9(1):8877.","journal-title":"Sci Rep"},{"issue":"6","key":"4115_CR89","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1159\/000489964","volume":"47","author":"N Maruyama","year":"2018","unstructured":"Maruyama N, Otsuki T, Yoshida Y, et al. Ferric citrate decreases fibroblast growth factor 23 and improves erythropoietin responsiveness in Hemodialysis patients. Am J Nephrol. 2018;47(6):406\u201314.","journal-title":"Am J Nephrol"},{"issue":"10","key":"4115_CR90","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1681\/ASN.2014080842","volume":"26","author":"K Umanath","year":"2015","unstructured":"Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. 2015;26(10):2578\u201387. https:\/\/doi.org\/10.1681\/ASN.2014080842.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4115_CR91","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1053\/j.ajkd.2021.03.020","volume":"78","author":"PE Pergola","year":"2021","unstructured":"Pergola PE, Kopyt NP. Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: a randomized trial and open-label extension. Am J Kidney Dis. 2021;78(6):846\u2013e561. https:\/\/doi.org\/10.1053\/j.ajkd.2021.03.020.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"4115_CR92","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1093\/ndt\/gfv277","volume":"30","author":"SN Fishbane","year":"2015","unstructured":"Fishbane SN, Singh AK, Cournoyer SH, et al. Ferric pyrophosphate citrate (Triferic\u2122) administration via the dialysate maintains hemoglobin and iron balance in chronic Hemodialysis patients. Nephrol Dial Transpl. 2015;30(12):2019\u201326. https:\/\/doi.org\/10.1093\/ndt\/gfv277.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4115_CR93","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/ndt\/gfu357","volume":"30","author":"A Pisani","year":"2015","unstructured":"Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transpl. 2015;30(4):645\u201352. https:\/\/doi.org\/10.1093\/ndt\/gfu357.","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"4115_CR94","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","volume":"323","author":"M Wolf","year":"2020","unstructured":"Wolf M, Rubin J, Achebe M, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA. 2020;323(5):432\u201343.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"4115_CR95","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2020-134435","volume":"136","author":"M Wolf","year":"2020","unstructured":"Wolf M, Schaefer B, Zoller H. Persistent hypophosphatemia after ferric carboxymaltose is associated with persistent changes in biomarkers of bone metabolism. Blood. 2020;136(Suppl 1):13\u20134.","journal-title":"Blood"},{"issue":"4","key":"4115_CR96","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","volume":"72","author":"H Zoller","year":"2023","unstructured":"Zoller H, Wolf M, Blumenstein I, et al. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut. 2023;72(4):644\u201353.","journal-title":"Gut"},{"issue":"5","key":"4115_CR97","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/bcp.14643","volume":"87","author":"B Schaefer","year":"2021","unstructured":"Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside\u2014a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(5):2256\u201373.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"4115_CR98","first-page":"65","volume":"75","author":"V Sari","year":"2017","unstructured":"Sari V, Atiqi R, Hoorn EJ, et al. Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation. Neth J Med. 2017;75(2):65\u201373.","journal-title":"Neth J Med"},{"issue":"7","key":"4115_CR99","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/14740338.2021.1912010","volume":"20","author":"I Blumenstein","year":"2021","unstructured":"Blumenstein I, Shanbhag S, Langguth P, et al. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects\u2014hypersensitivity, hypophosphatemia, and cardiovascular safety. Expert Opin Drug Saf. 2021;20(7):757\u201369.","journal-title":"Expert Opin Drug Saf"},{"key":"4115_CR100","unstructured":"National Collaborating Centre for Chronic Conditions, Royal College of Physicians. Guideline on anaemia management in chronic kidney disease. 2015. National Institute for Clinical Excellence. Available from: http:\/\/www.nice.org.uk\/guidance\/NG8\/evidence. Accessed 1st December 2024."},{"issue":"Suppl 2","key":"4115_CR101","first-page":"1","volume":"19","author":"F Locatelli","year":"2004","unstructured":"Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transpl. 2004;19(Suppl 2):1\u201347.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"4115_CR102","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/hdi.13054","volume":"27","author":"AJ Nashwan","year":"2023","unstructured":"Nashwan AJ, Yassin MA, Abd-Alrazaq A, et al. Hepatic and cardiac iron overload quantified by magnetic resonance imaging in patients on hemodialysis: A systematic review and meta-analysis. Hemodial Int. 2023;27(1):3\u201311. https:\/\/doi.org\/10.1111\/hdi.13054.","journal-title":"Hemodial Int"},{"key":"4115_CR103","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2215\/CJN.01070308","volume":"3","author":"M Rambod","year":"2008","unstructured":"Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in haemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol. 2008;3:1691\u2013701.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4115_CR104","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.amjmed.2012.01.015","volume":"125","author":"G Rostoker","year":"2012","unstructured":"Rostoker G, Griuncelli M, Loridon C, et al. Haemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med. 2012;125:991\u20139.","journal-title":"Am J Med"},{"issue":"12","key":"4115_CR105","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1093\/ndt\/gfs488","volume":"28","author":"NC van der Weerd","year":"2013","unstructured":"van der Weerd NC, Grooteman MP, Bots ML, et al. CONTRAST investigators. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transpl. 2013;28(12):3062\u201371. https:\/\/doi.org\/10.1093\/ndt\/gfs488.","journal-title":"Nephrol Dial Transpl"},{"key":"4115_CR106","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ebiom.2018.11.020","volume":"39","author":"G Rostoker","year":"2019","unstructured":"Rostoker G, Loridon C, Griuncelli M, et al. Liver Iron load influences hepatic fat fraction in End-Stage renal disease patients on dialysis: A proof of concept study. EBioMedicine. 2019;39:461\u201371. https:\/\/doi.org\/10.1016\/j.ebiom.2018.11.020.","journal-title":"EBioMedicine"},{"issue":"2","key":"4115_CR107","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/j.jrn.2022.08.004","volume":"33","author":"WH Ibrahim","year":"2023","unstructured":"Ibrahim WH, Abokresha MM, Nigm DA, et al. Relation of liver siderosis to liver fibrosis in Hemodialysis patients with severe hyperferritinemia secondary to high doses of intravenous Iron supplementation. J Ren Nutr. 2023;33(2):337\u201345. https:\/\/doi.org\/10.1053\/j.jrn.2022.08.004.","journal-title":"J Ren Nutr"},{"key":"4115_CR108","unstructured":"Overview | Chronic kidney disease: assessment and management | Guidance | NICE [Internet]. NICE. 2021 [cited 2024 Dec 7]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng203"},{"issue":"12","key":"4115_CR109","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/nep.12940","volume":"22","author":"SD Roger","year":"2017","unstructured":"Roger SD, Tio M, Park HC, Choong HL, Goh B, Cushway TR, et al. Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: A systematic review and meta-analysis. Nephrol Carlton Vic. 2017;22(12):969\u201376.","journal-title":"Nephrol Carlton Vic"},{"issue":"6","key":"4115_CR110","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s40620-023-01571-6","volume":"36","author":"S Bhandari","year":"2023","unstructured":"Bhandari S, Parfrey P, White C, Anker SD, Farrington K, Ford I, et al. Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes. J Nephrol. 2023;36(6):1651\u201362.","journal-title":"J Nephrol"},{"issue":"6","key":"4115_CR111","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/13696998.2019.1588738","volume":"22","author":"B Spinowitz","year":"2019","unstructured":"Spinowitz B, Pecoits-Filho R, Winkelmayer WC, Pergola PE, Rochette S, Thompson-Leduc P, et al. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ. 2019;22(6):593\u2013604.","journal-title":"J Med Econ"},{"issue":"1","key":"4115_CR112","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12882-020-01912-8","volume":"21","author":"M Guedes","year":"2020","unstructured":"Guedes M, Guetter CR, Erbano LHO, Palone AG, Zee J, Robinson BM, et al. Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis. BMC Nephrol. 2020;21(1):259.","journal-title":"BMC Nephrol"},{"key":"4115_CR113","unstructured":"National Kidney Federation [Internet]. 2022 [cited 2024 Dec 8]. UK Renal Registry 24th Annual Report Now Available. Available from: https:\/\/www.kidney.org.uk\/news\/uk-renal-registry-24h-annual-report-now-available"},{"issue":"2","key":"4115_CR114","first-page":"CD010590","volume":"2","author":"EY Chung","year":"2023","unstructured":"Chung EY, Palmer SC, Saglimbene VM, Craig JC, Tonelli M, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2023;2(2):CD010590.","journal-title":"Cochrane Database Syst Rev"},{"key":"4115_CR115","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.critrevonc.2018.06.010","volume":"129","author":"LH Arantes","year":"2018","unstructured":"Arantes LH, Crawford J, Gascon P, Latymer M, Launay-Vacher V, Rolland C, et al. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. Crit Rev Oncol Hematol. 2018;129:79\u201390.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4115_CR116","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1056\/NEJM199808273390902","volume":"339","author":"JS Kaufman","year":"1998","unstructured":"Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JK, Vaamonde CA, for the Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. Subcutaneous compared with intravenous Epoetin in patients receiving Hemodialysis 1998. N Engl J Med. 1998;339:578\u201383. https:\/\/doi.org\/10.1056\/NEJM199808273390902.","journal-title":"N Engl J Med"},{"key":"4115_CR117","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1053\/j.ajkd.2015.02.339","volume":"66","author":"WC Winkelmayer","year":"2015","unstructured":"Winkelmayer WC, Chang TI, Mitani AA. Longer-term outcomes of Darbepoetin Alfa versus Epoetin Alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis. 2015;66:106\u201313. https:\/\/doi.org\/10.1053\/j.ajkd.2015.02.339.","journal-title":"Am J Kidney Dis"},{"key":"4115_CR118","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1681\/ASN.2018101007","volume":"30","author":"Y Sakaguchi","year":"2019","unstructured":"Sakaguchi Y, Hamano T, Wada A. Types of erythropoietin-stimulating agents and mortality among patients undergoing Hemodialysis. J Am Soc Nephrol. 2019;30:1037\u201348. https:\/\/doi.org\/10.1681\/ASN.2018101007.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 2","key":"4115_CR119","first-page":"ii1","volume":"19","author":"F Locatelli","year":"2004","unstructured":"Locatelli F, Aljama P, B\u00e1r\u00e1ny P, Canaud B, Carrera F, Eckardt KU, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transpl. 2004;19(Suppl 2):ii1\u201347.","journal-title":"Nephrol Dial Transpl"},{"issue":"1 Suppl 1","key":"4115_CR120","first-page":"S182","volume":"37","author":"National Kidney Foundation","year":"2001","unstructured":"National Kidney Foundation. KDOQI clinical practice guidelines for Anemia of chronic kidney disease: update 2000. Am J Kidney Dis. 2001;37(1 Suppl 1):S182\u2013238.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 4","key":"4115_CR121","first-page":"43","volume":"15","author":"WH H\u00f6rl","year":"2000","unstructured":"H\u00f6rl WH, Jacobs C, Macdougall IC, Valderr\u00e1bano F, Parrondo I, Thompson K, et al. European best practice guidelines 14\u201316: inadequate response to Epoetin. Nephrol dial transplant off publ Eur dial transpl assoc -. Eur Ren Assoc. 2000;15(Suppl 4):43\u201350.","journal-title":"Eur Ren Assoc"},{"issue":"4","key":"4115_CR122","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","author":"JJV McMurray","year":"2012","unstructured":"McMurray JJV, Parfrey PS, Adamson JW, Aljama P, Berns JS, Bohlius J, et al. Kidney disease: improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279\u2013335.","journal-title":"Kidney Int Suppl"},{"key":"4115_CR123","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/00007890-199709270-00021","volume":"64","author":"LF Morrone","year":"1997","unstructured":"Morrone LF, Di Paolo S, Logoluso F, et al. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis on kidney transplant recipients: role of growth factors and cytokines. Transplantation. 1997;64:913\u20138.","journal-title":"Transplantation"},{"key":"4115_CR124","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1172\/JCI118484","volume":"97","author":"M Azizi","year":"1996","unstructured":"Azizi M, Rousseau A, Ezan E, et al. Acute angiotensin-converting enzyme Inhibition increases the plasma levels of the natural stem cell regulator N\u2010acetyl\u2010seryl\u2010aspartyl\u2010lysylproline. J Clin Invest. 1996;97:839\u201344.","journal-title":"J Clin Invest"},{"key":"4115_CR125","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1161\/CIRCULATIONAHA.105.549121","volume":"112","author":"P van der Meer","year":"2005","unstructured":"van der Meer P, Lipsic E, Westenbrink BD, et al. Levels of hematopoiesis inhibitor N-acetyl\u2010seryl\u2010aspartyl\u2010lysylproline partially explain the occurrence of anemia in heart failure. Circulation. 2005;112:1743\u20137.","journal-title":"Circulation"},{"issue":"Suppl 2","key":"4115_CR126","first-page":"ii1","volume":"19","author":"F Locatelli","year":"2004","unstructured":"Locatelli F, Aljama P, Barany Petal, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transpl. 2004;19(Suppl 2):ii1\u201347.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"4115_CR127","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1111\/j.1523-1755.2005.00340.x","volume":"67","author":"K Boven","year":"2005","unstructured":"Boven K, Stryker S, Knight J, Thomas A, van Regenmortel M, Kemeny DM, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005;67(6):2346\u201353.","journal-title":"Kidney Int"},{"issue":"10","key":"4115_CR128","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1097\/01.ASN.0000140219.28618.9F","volume":"15","author":"D Cournoyer","year":"2004","unstructured":"Cournoyer D, Toffelmire EB, Wells GA, Barber DL, Barrett BJ, Delage R, et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with Recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol JASN. 2004;15(10):2728\u201334.","journal-title":"J Am Soc Nephrol JASN"},{"issue":"7","key":"4115_CR129","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1056\/NEJMoa011931","volume":"346","author":"N Casadevall","year":"2002","unstructured":"Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure Red-Cell aplasia and antierythropoietin antibodies in patients treated with Recombinant erythropoietin. N Engl J Med. 2002;346(7):469\u201375.","journal-title":"N Engl J Med"},{"issue":"2","key":"4115_CR130","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/01.ASN.0000107561.59698.42","volume":"15","author":"J Rossert","year":"2004","unstructured":"Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol JASN. 2004;15(2):398\u2013406.","journal-title":"J Am Soc Nephrol JASN"},{"issue":"5","key":"4115_CR131","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/ndt\/gfg182","volume":"18","author":"K Eckardt","year":"2003","unstructured":"Eckardt K, Casadevall N. Pure red-cell aplasia due to anti\u2010erythropoietin antibodies. Nephrol Dial Transpl. 2003;18(5):865\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"9","key":"4115_CR132","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1097\/01.ASN.0000027031.79843.6C","volume":"13","author":"G Weber","year":"2002","unstructured":"Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different Epoetins. J Am Soc Nephrol JASN. 2002;13(9):2381\u20133.","journal-title":"J Am Soc Nephrol JASN"},{"issue":"1","key":"4115_CR133","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2215\/CJN.02440607","volume":"3","author":"C Pollock","year":"2008","unstructured":"Pollock C, Johnson DW, H\u00f6rl WH, Rossert J, Casadevall N, Schellekens H, et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol CJASN. 2008;3(1):193\u20139.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"6","key":"4115_CR134","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1600-0609.2004.00348.x","volume":"73","author":"N Casadevall","year":"2004","unstructured":"Casadevall N, Cournoyer D, Marsh J, Messner H, Pallister C, Parker-Williams J, et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol. 2004;73(6):389\u201396.","journal-title":"Eur J Haematol"},{"issue":"10","key":"4115_CR135","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood-2005-02-0508","volume":"106","author":"CL Bennett","year":"2005","unstructured":"Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with Recombinant Epoetin: a follow-up report from the research on adverse drug events and reports (RADAR) project. Blood. 2005;106(10):3343\u20137.","journal-title":"Blood"},{"issue":"9423","key":"4115_CR136","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/S0140-6736(04)16302-2","volume":"363","author":"D Verhelst","year":"2004","unstructured":"Verhelst D, Rossert J, Casadevall N, Kr\u00fcger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell Aplasia: a retrospective study. Lancet Lond Engl. 2004;363(9423):1768\u201371.","journal-title":"Lancet Lond Engl"},{"key":"4115_CR137","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41581-019-0182-z","volume":"15","author":"J Schidel","year":"2019","unstructured":"Schidel J, Ratcliffe PJ. Mechanisms of hypoxia signalling: new implications for nephrology. Nat Rev Nephrol. 2019;15:641\u201359.","journal-title":"Nat Rev Nephrol"},{"key":"4115_CR138","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1111\/bph.13188","volume":"172","author":"TD Barrett","year":"2015","unstructured":"Barrett TD, Palomino HL, Brondstetter TI, et al. Prolyl hydroxylase Inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015;172:4078\u2013c4088.","journal-title":"Br J Pharmacol"},{"key":"4115_CR139","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1172\/JCI30117","volume":"117","author":"EB Rankin","year":"2007","unstructured":"Rankin EB, Biju MP, Liu Q, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007;117:1068\u201377.","journal-title":"J Clin Invest"},{"key":"4115_CR140","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631\u20134.","journal-title":"J Am Soc Nephrol"},{"key":"4115_CR141","unstructured":"NICE. Final appraisal document \u2013 Roxadustat for treating anaemia in people with chronic kidney disease. Issue date: June 2022 Available at: https:\/\/www.nice.org.uk\/guidance\/ta807\/documents\/final-appraisal-determination-document Accessed 16.09.23."},{"issue":"11","key":"4115_CR142","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1681\/ASN.20223311S1244a","volume":"33","author":"KL Johansen","year":"2022","unstructured":"Johansen KL, et al. Effects of Daprodustat on hemoglobin and quality of life in Non-Dialysis CKD patients: expanded results of the ASCEND-NHQ trial. J Am Soc Nephrol. 2022;33(11):244.","journal-title":"J Am Soc Nephrol"},{"key":"4115_CR143","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381:1001\u201310.","journal-title":"N Engl J Med"},{"key":"4115_CR144","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381:1011\u201322.","journal-title":"N Engl J Med"},{"key":"4115_CR145","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ekir.2021.04.003","volume":"6","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Iwasaki M, Otsuka T, et al. Phase 3 study of Roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney Int Rep. 2021;6:1810\u201328.","journal-title":"Kidney Int Rep"},{"key":"4115_CR146","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","volume":"36","author":"R Provenzano","year":"2021","unstructured":"Provenzano R, Shutov E, Eremeeva L, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transpl. 2021;36:1717\u201330.","journal-title":"Nephrol Dial Transpl"},{"key":"4115_CR147","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","volume":"6","author":"C Charytan","year":"2021","unstructured":"Charytan C, Manllo-Karim R, Martin ER, et al. A randomized trial of Roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep. 2021;6:1829\u201339.","journal-title":"Kidney Int Rep"},{"key":"4115_CR148","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2020111638","volume":"33","author":"S Fishbane","year":"2022","unstructured":"Fishbane S, Pollock CA, El-Shahawy M, et al. Roxadustat versus Epoetin Alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study. J Am Soc Nephrol. 2022;33:850\u201366.","journal-title":"J Am Soc Nephrol"},{"key":"4115_CR149","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2019060623","volume":"31","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Iwasaki M, Yamaguchi Y, et al. Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral Roxadustat in CKD patients with anemia on Hemodialysis in Japan. J Am Soc Nephrol. 2020;31:1628\u201339.","journal-title":"J Am Soc Nephrol"},{"key":"4115_CR150","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jfma.2021.06.004","volume":"121","author":"YP Hou","year":"2022","unstructured":"Hou YP, Mao XY, Wang C, et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. J Formos Med Assoc. 2022;121:529\u201338.","journal-title":"J Formos Med Assoc"},{"key":"4115_CR151","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","volume":"384","author":"KU Eckardt","year":"2021","unstructured":"Eckardt KU, Agarwal R, Aswad A, et al. Safety and efficacy of Vadadustat for anemia in patients undergoing dialysis. N Engl J Med. 2021;384:1601\u201312.","journal-title":"N Engl J Med"},{"key":"4115_CR152","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/ndt\/gfab055","volume":"36","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Kondo K, Ueta K, et al. Efficacy and safety of Vadadustat compared with Darbepoetin Alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study. Nephrol Dial Transpl. 2021;36:1731\u201341.","journal-title":"Nephrol Dial Transpl"},{"key":"4115_CR153","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1681\/ASN.2020091311","volume":"32","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Kondo K, Kokado Y, et al. Phase 3 randomized study comparing Vadadustat with Darbepoetin Alfa for anemia in Japanese patients with nondialysis-dependent CKD. J Am Soc Nephrol. 2021;32:1779\u201390.","journal-title":"J Am Soc Nephrol"},{"key":"4115_CR154","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","volume":"384","author":"GM Chertow","year":"2021","unstructured":"Chertow GM, Pergola PE, Farag YMK, et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med. 2021;384:1589\u2013600.","journal-title":"N Engl J Med"},{"key":"4115_CR155","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000513103","volume":"52","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Hamano T, Akizawa T, et al. Daprodustat compared with Epoetin beta Pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. Am J Nephrol. 2021;52:26\u201335.","journal-title":"Am J Nephrol"},{"key":"4115_CR156","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","volume":"385","author":"AK Singh","year":"2021","unstructured":"Singh AK, Carroll K, McMurray JJV, et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med. 2021;385:2313\u201324.","journal-title":"N Engl J Med"},{"key":"4115_CR157","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","volume":"385","author":"AK Singh","year":"2021","unstructured":"Singh AK, Carroll K, Perkovic V, et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. N Engl J Med. 2021;385:2325\u201335.","journal-title":"N Engl J Med"},{"key":"4115_CR158","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/1744-9987.13686","volume":"25","author":"H Kanai","year":"2021","unstructured":"Kanai H, Nangaku M, Nagai R, et al. Efficacy and safety of Daprodustat in Japanese peritoneal dialysis patients. Ther Apher Dial. 2021;25:979\u201387.","journal-title":"Ther Apher Dial"},{"key":"4115_CR159","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/jamainternmed.2022.0605","volume":"182","author":"AK Singh","year":"2022","unstructured":"Singh AK, Cizman B, Carroll K, et al. Efficacy and safety of Daprodustat for treatment of anemia of chronic kidney dis- ease in incident dialysis patients: a randomized clinical trial. JAMA Intern Med. 2022;182:592\u2013602.","journal-title":"JAMA Intern Med"},{"key":"4115_CR160","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2215\/CJN.16011219","volume":"15","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Nangaku M, Yonekawa T, et al. Efficacy and safety of Daprodustat compared with Darbepoetin Alfa in Japanese Hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clin J Am Soc Nephrol. 2020;15:1155\u201365.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4115_CR161","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2215\/CJN.00550122","volume":"17","author":"DW Coyne","year":"2022","unstructured":"Coyne DW, Singh AK, Lopes RD, et al. Three times weekly dosing of Daprodustat versus conventional Epoetin for treatment of anemia in Hemodialysis patients: ASCEND-TD: a phase 3 randomized, double-blind, noninferiority trial. Clin J Am Soc Nephrol. 2022;17:1325\u201336.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4115_CR162","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000523961","volume":"53","author":"D Agrawal","year":"2022","unstructured":"Agrawal D, Varade D, Shah H, et al. Desidustat in Anemia due to Non-Dialysis-Dependent chronic kidney disease: a phase 3 study (DREAM-ND). Am J Nephrol. 2022;53:352\u201360.","journal-title":"Am J Nephrol"},{"key":"4115_CR163","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000523949","volume":"53","author":"S Gang","year":"2022","unstructured":"Gang S, Khetan P, Varade D, et al. Desidustat in Anemia due to Dialysis-Dependent chronic kidney disease: a phase 3 study (DREAM-D). Am J Nephrol. 2022;53:343\u201351.","journal-title":"Am J Nephrol"},{"key":"4115_CR164","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.ekir.2021.04.037","volume":"6","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Nangaku M, Yamaguchi T, et al. A phase 3 study of Enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney Int Rep. 2021;6:1840\u20139.","journal-title":"Kidney Int Rep"},{"key":"4115_CR165","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1159\/000517053","volume":"7","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Nangaku M, Yamaguchi T, et al. A phase 3 study of Enarodustat (JTZ-951) in Japanese Hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study. Kidney Dis (Basel). 2021;7:494\u2013502.","journal-title":"Kidney Dis (Basel)"},{"key":"4115_CR166","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000496929","volume":"49","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Nangaku M, Yamaguchi T, et al. A placebo-controlled, randomized trial of Enarodustat in patients with chronic kidney disease followed by long-term trial. Am J Nephrol. 2019;49:165\u201374.","journal-title":"Am J Nephrol"},{"key":"4115_CR167","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1159\/000518071","volume":"52","author":"H Yamamoto","year":"2021","unstructured":"Yamamoto H, Nobori K, Matsuda Y, et al. Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. Am J Nephrol. 2021;52:871\u201383.","journal-title":"Am J Nephrol"},{"key":"4115_CR168","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1159\/000518072","volume":"52","author":"H Yamamoto","year":"2021","unstructured":"Yamamoto H, Nobori K, Matsuda Y, et al. Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. Am J Nephrol. 2021;52:884\u201393.","journal-title":"Am J Nephrol"},{"key":"4115_CR169","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/1744-9987.13627","volume":"25","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Nobori K, Matsuda Y, et al. Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study. Ther Apher Dial. 2021;25:917\u201325.","journal-title":"Ther Apher Dial"},{"key":"4115_CR170","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2215\/CJN.02510218","volume":"14","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, Akizawa T, Berns JS, et al. Effects of molidustat in the treatment of anemia in CKD. Clin J Am Soc Nephrol. 2019;14:28\u201339.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4115_CR171","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/j.ekir.2021.07.015","volume":"6","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Yamada T, Nobori K, et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney Int Rep. 2021;6:2604\u201316.","journal-title":"Kidney Int Rep"},{"key":"4115_CR172","first-page":"CD013751","volume":"8","author":"P Natale","year":"2022","unstructured":"Natale P, Palmer SC, Jaure A, et al. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022;8:CD013751.","journal-title":"Cochrane Database Syst Rev"},{"key":"4115_CR173","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1053\/j.ajkd.2022.09.014","volume":"81","author":"Q Zheng","year":"2023","unstructured":"Zheng Q, Wang Y, Yang H, et al. Cardiac and kidney adverse effects of HIF prolyl-hydroxylase inhibitors for anemia in patients with CKD not receiving dialysis: a systematic re- view and meta-analysis. Am J Kidney Dis. 2023;81:434\u2013e451.","journal-title":"Am J Kidney Dis"},{"key":"4115_CR174","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/ckj\/sfac271","volume":"16","author":"K Takkavatakarn","year":"2023","unstructured":"Takkavatakarn K, Thammathiwat T, Phannajit J, et al. The impacts of hypoxia-inducible factor stabilizers on labora- Tory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic review and meta-analysis. Clin Kidney J. 2023;16:845\u201358.","journal-title":"Clin Kidney J"},{"key":"4115_CR175","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/jcpt.13385","volume":"46","author":"H Chen","year":"2021","unstructured":"Chen H, Cheng Q, Wang J, et al. Long-term efficacy and safety of hypoxia-inducible factor Prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta-analysis including 13,146 patients. J Clin Pharm Ther. 2021;46:999\u20131009.","journal-title":"J Clin Pharm Ther"},{"key":"4115_CR176","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.21037\/atm-21-4357","volume":"9","author":"B Abdelazeem","year":"2021","unstructured":"Abdelazeem B, Abbas KS, Shehata J, et al. The efficacy of Roxadustat for the treatment of anemia in dialysis de- pendent chronic kidney disease patients: an updated sys- tematic review and meta-analysis of randomized clinical trials. Ann Transl Med. 2021;9:1714.","journal-title":"Ann Transl Med"},{"key":"4115_CR177","first-page":"105256","volume":"163","author":"J Li","year":"2021","unstructured":"Li J, Xie QH, You L, et al. Effects of hypoxia-inducible factor Prolyl hydroxylase inhibitors on iron regulation in non- dialysis-dependent chronic kidney disease patients with anemia: a systematic review and meta-analysis. Pharma- Col Res. 2021;163:105256.","journal-title":"Pharma- Col Res"},{"key":"4115_CR178","doi-asserted-by":"publisher","first-page":"105020","DOI":"10.1016\/j.phrs.2020.105020","volume":"159","author":"Q Zheng","year":"2020","unstructured":"Zheng Q, Yang H, Sun L, et al. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs Epoetin and Darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: a network meta-analysis. Pharmacol Res. 2020;159:105020.","journal-title":"Pharmacol Res"},{"key":"4115_CR179","doi-asserted-by":"crossref","unstructured":"Minutolo R, Liberti ME, Simeon V, Sasso FC, Borrelli S, De Nicola L, Garofalo C. Efficacy and safety of hypoxia-inducible factor Prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials. Clin Kidney J. 2023.","DOI":"10.1093\/ckj\/sfad143"},{"key":"4115_CR180","unstructured":"Evrenzo- SPC. Available at: Evrenzo (roxadustat) film coated tablets (Great Britain) - Summary of product characteristics (SmPC) - (emc). 2023. medicines.org.uk. Accessed 16 Sept 2023."},{"key":"4115_CR181","doi-asserted-by":"publisher","first-page":"145796","DOI":"10.1016\/j.gene.2021.145796","volume":"798","author":"M Rashid","year":"2021","unstructured":"Rashid M, Zadeh LR, Baradaran B, et al. Up-down regulation of HIF-1\u03b1 in cancer progression. Gene. 2021;798:145796.","journal-title":"Gene"},{"key":"4115_CR182","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.2174\/138161209789649394","volume":"15","author":"VH Haase","year":"2009","unstructured":"Haase VH. The VHL tumor suppressor: master regulator of HIF. Curr Pharm Des. 2009;15:3895\u2013903.","journal-title":"Curr Pharm Des"},{"key":"4115_CR183","doi-asserted-by":"publisher","first-page":"109524","DOI":"10.1016\/j.cellsig.2020.109524","volume":"69","author":"B Buchholz","year":"2020","unstructured":"Buchholz B, Eckardt KU. Role of oxygen and the HIF-pathway in polycystic kidney disease. Cell Signal. 2020;69:109524.","journal-title":"Cell Signal"},{"key":"4115_CR184","doi-asserted-by":"publisher","first-page":"e111838","DOI":"10.1371\/journal.pone.0111838","volume":"9","author":"I Flamme","year":"2014","unstructured":"Flamme I, Oehme F, Ellinghaus P, et al. Mimicking hypoxia to treat anemia: HIF stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS ONE. 2014;9:e111838.","journal-title":"PLoS ONE"},{"key":"4115_CR185","doi-asserted-by":"publisher","first-page":"e133690","DOI":"10.1172\/jci.insight.133690","volume":"6","author":"J Yu","year":"2021","unstructured":"Yu J, Wang S, Shi W, et al. Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS. JCI Insight. 2021;6:e133690.","journal-title":"JCI Insight"},{"issue":"Suppl 1","key":"4115_CR186","first-page":"S110","volume":"21 Suppl 1","author":"VH Haase","year":"2017","unstructured":"Haase VH. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodial Int Int Symp Home Hemodial. 2017;21 Suppl 1(Suppl 1):S110\u201324.","journal-title":"Hemodial Int Int Symp Home Hemodial"},{"issue":"6","key":"4115_CR187","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/1744-9987.13839","volume":"26","author":"M Nangaku","year":"2022","unstructured":"Nangaku M, et al. Safety of Daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan. Therapeutic Apheresis Dialysis: Official J Int Soc Apheresis Japanese Soc Apheresis Japanese Soc Dialysis Therapy. 2022;26(6):1065\u201378.","journal-title":"Therapeutic Apheresis Dialysis: Official J Int Soc Apheresis Japanese Soc Apheresis Japanese Soc Dialysis Therapy"},{"key":"4115_CR188","unstructured":"FDA. Roxadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients not on Dialysis and on Dialysis. FDA Presentation: Cardiovascular and Renal Drugs Advisory Committee Meeting. 2021. Available at: https:\/\/www.fda.gov\/media\/150756\/download. Accessed August 28, 2023."},{"key":"4115_CR189","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/nep.13835","volume":"26","author":"DYH Yap","year":"2021","unstructured":"Yap DYH, McMahon LP, Hao CM, et al. Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Nephrol (Carlton). 2021;26:105\u201318.","journal-title":"Nephrol (Carlton)"},{"key":"4115_CR190","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1161\/CIRCRESAHA.119.316453","volume":"127","author":"X Tang","year":"2020","unstructured":"Tang X, Fang M, Cheng R, et al. Iron-Deficiency and Estrogen are associated with ischemic stroke by Up-Regulating transferrin to induce hypercoagulability. Circ Res. 2020;127:651\u201363.","journal-title":"Circ Res"},{"key":"4115_CR191","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.thromres.2019.07.013","volume":"181","author":"N Gupta","year":"2019","unstructured":"Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77\u201383.","journal-title":"Thromb Res"},{"key":"4115_CR192","unstructured":"FDA. Cardiovascular and Renal Drugs Advisory Committee Meeting - Roxadustat. https:\/\/www.fda.gov\/media\/150728\/download. Accessed August 28, 2023."},{"key":"4115_CR193","unstructured":"Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients. Pressrelease, March 30. 2022. https:\/\/ir.akebia.com\/news-releases\/news-releasedetails\/akebia-therapeutics-receives-complete-response-letter-fda. Accessed Augus 29, 2023."},{"key":"4115_CR194","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1007\/s12325-021-01903-7","volume":"38","author":"J Barratt","year":"2021","unstructured":"Barratt J, Sulowicz W, Schomig M, et al. Efficacy and cardiovascular safety of Roxadustat in dialysis-dependent chronic kidney disease: pooled analysis of four phase 3 studies. Adv Ther. 2021;38:5345\u201360.","journal-title":"Adv Ther"},{"key":"4115_CR195","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2215\/CJN.08280621","volume":"16","author":"WC Winkelmayer","year":"2021","unstructured":"Winkelmayer WC, Walther CP. Cardiovascular safety of Roxadustat in CKD anemia: a Fig leaf named noninferiority. Clin J Am Soc Nephrol. 2021;16:1155\u20137.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4115_CR196","doi-asserted-by":"publisher","first-page":"6201","DOI":"10.3390\/ijms24076201","volume":"24","author":"PG Sant\u2019Ana","year":"2023","unstructured":"Sant\u2019Ana PG, Tomasi LC, Murata GM, et al. Hypoxia- inducible factor 1-alpha and glucose metabolism during cardiac remodeling progression from hypertrophy to heart failure. Int J Mol Sci. 2023;24:6201.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4115_CR197","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1034\/j.1600-6143.2002.20506.x","volume":"2","author":"PD Yorgin","year":"2002","unstructured":"Yorgin PD, Scandling JD, Belson A, et al. Late post-transplant anaemia in adult renal transplant recipients. An under-recognized problem? Am J Transpl. 2002;2(5):429\u201335.","journal-title":"Am J Transpl"},{"issue":"6","key":"4115_CR198","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1053\/ajkd.2002.36910","volume":"40","author":"PD Yorgin","year":"2002","unstructured":"Yorgin PD, Belson A, Sanchez J, et al. Unexpectedly high prevalence of post-transplant anaemia in paediatric and young adult renal transplant recipients. Am J Kidney Dis. 2002;40(6):1306\u201318.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"4115_CR199","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1034\/j.1600-6143.2003.00133.x","volume":"3","author":"Y Vanrenterghem","year":"2003","unstructured":"Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anaemia in renal transplant recipients: A European survey. Am J Transpl. 2003;3(7):835\u201345.","journal-title":"Am J Transpl"},{"issue":"6","key":"4115_CR200","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1432-2277.2000.tb01023.x","volume":"13","author":"KA Abraham","year":"2000","unstructured":"Abraham KA, Little MA, Dorman AM, et al. Haemolytic-uremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int. 2000;13(6):443\u20137.","journal-title":"Transpl Int"},{"issue":"3","key":"4115_CR201","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0272-6386(12)80486-0","volume":"17","author":"M Epstein","year":"1991","unstructured":"Epstein M, Landsberg D. Cyclosporine-induced thrombotic microangiopathy resulting in renal allograft loss and its successful reuse: A report of two cases. Am J Kidney Dis. 1991;17(3):346\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"4115_CR202","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1053\/ajkd.2000.17690","volume":"36","author":"PT Pham","year":"2000","unstructured":"Pham PT, Peng A, Wilkinson AH, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis. 2000;36(4):844\u201350.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"4115_CR203","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/00007890-199902270-00009","volume":"67","author":"HM Trimarchi","year":"1999","unstructured":"Trimarchi HM, Truong LD, Brennan S, et al. Report of two cases and review of the literature. Transplantation. 1999;67(4):539\u201344.","journal-title":"Transplantation"},{"issue":"6","key":"4115_CR204","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1046\/j.1523-1755.1999.00492.x","volume":"55","author":"A Zarifian","year":"1999","unstructured":"Zarifian A, Meleg-Smith S, O\u2019donovan R, et al. Cyclosporine associated thrombotic microangiopathy in renal allografts. Kidney Int. 1999;55(6):2457\u201366.","journal-title":"Kidney Int"},{"issue":"8","key":"4115_CR205","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/ndt\/9.8.1191","volume":"9","author":"B Dussol","year":"1994","unstructured":"Dussol B, Brunet P, Vacher-Coponat H, et al. Haemolytic uraemic syndrome in a renal transplant recipient during OKT3 therapy. Nephrol Dial Transpl. 1994;9(8):1191\u20133.","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"4115_CR206","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/j.1432-2277.1996.tb01001.x","volume":"9","author":"G Morris-Stiff","year":"1996","unstructured":"Morris-Stiff G, Evans M, Baboolal K, et al. Haemolytic uraemic syndrome associated with OKT3. Transpl Int. 1996;9(5):522\u20133.","journal-title":"Transpl Int"},{"issue":"2","key":"4115_CR207","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","volume":"71","author":"AS MacDonald","year":"2001","unstructured":"MacDonald AS, RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001;71(2):271\u201380.","journal-title":"Transplantation"},{"issue":"3 Suppl","key":"4115_CR208","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/S0041-1345(03)00351-8","volume":"35","author":"BD Kahan","year":"2003","unstructured":"Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the university of Texas at Houston experience. Transpl Proc. 2003;35(3 Suppl):S25\u201334.","journal-title":"Transpl Proc"},{"issue":"12","key":"4115_CR209","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1111\/j.1600-6143.2004.00612.x","volume":"4","author":"JJ Augustine","year":"2004","unstructured":"Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transpl. 2004;4(12):2001\u20136.","journal-title":"Am J Transpl"},{"issue":"1","key":"4115_CR210","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/ndt\/gfh334","volume":"20","author":"RJ Crew","year":"2005","unstructured":"Crew RJ, Radhakrishnan J, Cohen DJ, et al. De Novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. Nephrol Dial Transpl. 2005;20(1):203\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4115_CR211","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/ki.2009.231","volume":"76","author":"S Fishbane","year":"2009","unstructured":"Fishbane S, et al. Posttransplant anemia: the role of sirolimus. Kidney Int. 2009;76(4):376\u201382.","journal-title":"Kidney Int"},{"issue":"5","key":"4115_CR212","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1097\/01.ASN.0000125551.59739.2E","volume":"15","author":"WC Winkelmayer","year":"2004","unstructured":"Winkelmayer WC, Kewalramani R, Rutstein M, et al. Pharmacoepidemiology of anaemia in kidney transplant recipients. J Am Soc Nephrol. 2004;15(5):1347\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4115_CR213","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1053\/ajkd.2001.26839","volume":"38","author":"Y Le Meur","year":"2001","unstructured":"Le Meur Y, Lorgeot V, Comte L, et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis. 2001;38(3):510\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"4115_CR214","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000072705","volume":"23","author":"M Naito","year":"2003","unstructured":"Naito M, Kawashima A, Akiba T, Takanashi M, et al. Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic haemodialysis patients. Am J Nephrol. 2003;23(5):287\u201393.","journal-title":"Am J Nephrol"},{"key":"4115_CR215","doi-asserted-by":"crossref","unstructured":"So BJ, Chae KM, Lee KK et al. Pure red cell aplasia due to parvovirus B19 infection in a renal transplant patient: A case report. Transplant Proc. 2000; 32(7):1954\u20136.","DOI":"10.1016\/S0041-1345(00)01509-8"},{"issue":"6","key":"4115_CR216","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/01.TP.0000149339.25047.F4","volume":"79","author":"LJ Vales-Albertos","year":"2005","unstructured":"Vales-Albertos LJ, Garc\u00eda-C\u00e1rdenas M, Ch\u00e1vez-Becerra S, et al. Pure red cell aplasia associated with parvovirus B19 infection in renal transplantation: the first case report in Mexico. Transplantation. 2005;79(6):739.","journal-title":"Transplantation"},{"issue":"6","key":"4115_CR217","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/S0041-1345(03)00774-7","volume":"35","author":"A Debska-Slizie\u0144","year":"2003","unstructured":"Debska-Slizie\u0144 A, Chamienia A, Kr\u00f3l E, et al. Haemolytic anaemia after renal transplantation: analysis of case reports. Transpl Proc. 2003;35(6):2233\u20137.","journal-title":"Transpl Proc"},{"issue":"4","key":"4115_CR218","first-page":"395","volume":"21","author":"R Peces","year":"2001","unstructured":"Peces R, D\u00edaz Corte C, Navascu\u00e9s RA. [Haemolytic anaemia caused by graft-versus host reaction in ABO-non identical renal transplants from blood group O donors]. Nefrologia. 2001;21(4):395\u2013401.","journal-title":"Nefrologia"},{"issue":"6","key":"4115_CR219","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000046202","volume":"20","author":"FK Li","year":"2000","unstructured":"Li FK, Chan TM, Lai KN. Alloimmune haemolysis after renal transplantation. Am J Nephrol. 2000;20(6):473\u20135.","journal-title":"Am J Nephrol"},{"issue":"3","key":"4115_CR220","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000188467","volume":"69","author":"B Moulin","year":"1995","unstructured":"Moulin B, Ollier J, George F. Serum erythropoietin and reticulocyte maturity index after renal transplantation: A prospective longitudinal study. Nephron. 1995;69(3):259\u201366.","journal-title":"Nephron"},{"issue":"4","key":"4115_CR221","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1399-0012.1997.tb00824.x","volume":"11","author":"AM Miles","year":"1997","unstructured":"Miles AM, Markell MS, Daskalakis P, et al. Anemia following renal transplantation: erythropoietin response and iron deficiency. Clin Transpl. 1997;11(4):313\u20135.","journal-title":"Clin Transpl"},{"key":"4115_CR222","doi-asserted-by":"crossref","unstructured":"Hassan S, Gleeson S, Thomson T, Spensley KJ, Dor F, Brown C et al. Clinical impact of early post-transplant red cell transfusions in kidney transplantation: a systematic review and meta-analysis. Front Transplantation. 2023;2.","DOI":"10.3389\/frtra.2023.1215130"},{"key":"4115_CR223","unstructured":"Excellence NIfHaC. Quality Standards for Blood Transfusion. NICE QS138. 2016. [Available from: https:\/\/www.nice.org.uk\/guidance\/qs138]. (last accessed 12th December 2024)."},{"key":"4115_CR224","unstructured":"Excellence NIfHaC. Guidelines for Blood Transfusion. NICE Guideline {NG24}. 2015. [Available from: https:\/\/www.nice.org.uk\/guidance\/ng24] (last accessed 12th December 2024)."},{"key":"4115_CR225","unstructured":"Transplant NBa. Patient Blood Management Tool Kit [Available from: https:\/\/hospital.blood.co.uk\/pbm-toolkit\/]. 2. (last accessed 12th December 2023)."},{"issue":"3","key":"4115_CR226","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1056\/NEJM198907203210304","volume":"321","author":"CH Sun","year":"1989","unstructured":"Sun CH, Ward H, Paul WL, Koyle MA, Yanagawa N, Lee DBN. Serum erythropoietin levels after renal transplantation. N Engl J Med. 1989;321(3):151\u20137.","journal-title":"N Engl J Med"},{"issue":"2","key":"4115_CR227","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1681\/ASN.2011060546","volume":"23","author":"G Choukroun","year":"2012","unstructured":"Choukroun G, Kamar N, Dussol B, Etienne I, Cassuto-Viguier E, Toupance O, et al. Correction of postkidney transplant Anemia reduces progression of allograft nephropathy. J Am Soc Nephrol. 2012;23(2):360\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"4115_CR228","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1093\/oxfordjournals.ndt.a027674","volume":"11","author":"A Van Loo","year":"1996","unstructured":"Van Loo A, Vanholder R, Bernaert P, De Roose J, Lameire N. Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study. Nephrol Dial Transpl. 1996;11(9):1815\u201321.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"4115_CR229","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1111\/ajt.15233","volume":"19","author":"S Hassan","year":"2019","unstructured":"Hassan S, Regan F, Brown C, Harmer A, Anderson N, Beckwith H, et al. Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post-renal transplantation. Am J Transpl. 2019;19(6):1720\u20139.","journal-title":"Am J Transpl"},{"key":"4115_CR230","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12882-019-1244-y","volume":"20","author":"A Schechter","year":"2019","unstructured":"Schechter A, Gafter-Gvili A, Shepshelovich D, et al. Post renal transplant anemia: severity, causes and their association with graft and patient survival. BMC Nephrol. 2019;20:51.","journal-title":"BMC Nephrol"},{"key":"4115_CR231","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1007\/s10157-019-01737-2","volume":"23","author":"M Okumi","year":"2019","unstructured":"Okumi M, Okabe Y, Unagami K, et al. The interaction between post-transplant anemia and allograft function in kidney transplantation: the Japan academic consortium of kidney Transplantation-II study. Clin Exp Nephrol. 2019;23:1066\u201375.","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"4115_CR232","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/j.1600-6143.2006.01727.x","volume":"7","author":"MZ Molnar","year":"2007","unstructured":"Molnar MZ, Czira M, Ambrus C, et al. Anemia is associated with mortality in kidney-transplanted patients\u2013a prospective cohort study. Am J Transpl. 2007;7(4):818\u201324.","journal-title":"Am J Transpl"},{"issue":"32","key":"4115_CR233","doi-asserted-by":"publisher","first-page":"e7735","DOI":"10.1097\/MD.0000000000007735","volume":"96","author":"A Gafter-Gvili","year":"2017","unstructured":"Gafter-Gvili A, Ayalon-Dangur I, Cooper L, et al. Posttransplantation anemia in kidney transplant recipients: A retrospective cohort study. Med (Baltim). 2017;96(32):e7735.","journal-title":"Med (Baltim)"},{"issue":"5","key":"4115_CR234","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1097\/00007890-199305000-00016","volume":"55","author":"R Schmidt","year":"1993","unstructured":"Schmidt R, Kupin W, Dumler F, et al. Influence of the pre-transplant hematocrit level on early graft function in primary cadaveric renal transplantation. Transplantation. 1993;55(5):1034\u201340.","journal-title":"Transplantation"},{"issue":"7","key":"4115_CR235","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/00007890-199610150-00024","volume":"62","author":"EM Vasquez","year":"1996","unstructured":"Vasquez EM, Pollack R. Effect of pre-transplant erythropoietin therapy on renal allograft outcome. Transplantation. 1996;62(7):1026\u20138.","journal-title":"Transplantation"},{"issue":"3","key":"4115_CR236","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/00002216-198907000-00117","volume":"35","author":"EP Paganini","year":"1989","unstructured":"Paganini EP, Braun WE, Latham D, et al. Renal transplantation: results in haemodialysis patients previously treated with Recombinant human erythropoietin. ASAIO Trans. 1989;35(3):535\u20138.","journal-title":"ASAIO Trans"},{"issue":"4 Suppl 1","key":"4115_CR237","first-page":"54","volume":"18","author":"DB Lee","year":"1991","unstructured":"Lee DB. Interrelationship between erythropoietin and erythropoiesis: insights from renal transplantation. Am J Kidney Dis. 1991;18(4 Suppl 1):54\u20136.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"4115_CR238","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/01.TP.0000150370.51700.99","volume":"79","author":"W Van Biesen","year":"2005","unstructured":"Van Biesen W, Vanholder R, Veys N, et al. Efficacy of erythropoietin administration in the treatment of anaemia immediately after renal transplantation. Transplantation. 2005;79(3):367\u20138.","journal-title":"Transplantation"},{"issue":"2","key":"4115_CR239","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/oxfordjournals.ndt.a092085","volume":"7","author":"KK Jindal","year":"1992","unstructured":"Jindal KK, Hirsch DJ, Belitsky P, et al. Low-dose subcutaneous erythropoietin corrects the anaemia of renal transplant failure. Nephrol Dial Transpl. 1992;7(2):143\u20136.","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"4115_CR240","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1681\/ASN.V551216","volume":"5","author":"N Muirhead","year":"1994","unstructured":"Muirhead N, Cattran DC, Zaltzman J, et al. Safety and efficacy of Recombinant human erythropoietin in correcting the anaemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol. 1994;5(5):1216\u201322.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"4115_CR241","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/ndt\/17.9.1667","volume":"17","author":"BN Becker","year":"2002","unstructured":"Becker BN, Becker YT, Leverson GE, Heisey DM. Erythropoietin therapy May retard progression in chronic renal transplant dysfunction. Nephrol Dial Transpl. 2002;17(9):1667\u201373.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"4115_CR242","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1681\/ASN.2011060546","volume":"23","author":"G Choukroun","year":"2012","unstructured":"Choukroun G, Kamar N, Dussol B, et al. For the CAPRIT study investigators. Correction of post kidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol. 2012;23(2):360\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"4115_CR243","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/ndt\/gfy365","volume":"34","author":"M Tsujita","year":"2019","unstructured":"Tsujita M, Kosugi T, Goto N, et al. The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial. Nephrol Dial Transpl. 2019;34(8):1409\u201316.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"4115_CR244","doi-asserted-by":"publisher","first-page":"27","DOI":"10.6002\/ect.2018.0283","volume":"18","author":"T Pile","year":"2020","unstructured":"Pile T, Raftery M, Thuraisingham R, Kirwan CJ, Harwood S, Yaqoob MM. Treating posttransplant Anemia with erythropoietin improves quality of life but does not affect progression of chronic kidney disease. Exp Clin Transpl. 2020;18(1):27\u201333.","journal-title":"Exp Clin Transpl"},{"issue":"1","key":"4115_CR245","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1399-0012.1994.tb00942.x","volume":"8","author":"O Traindl","year":"1994","unstructured":"Traindl O, Barnas U, Franz M, et al. Recombinant human erythropoietin in renal transplant recipients with renal anaemia. Clin Transpl. 1994;8(1):45\u20138.","journal-title":"Clin Transpl"},{"issue":"3","key":"4115_CR246","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/00007890-198909000-00038","volume":"48","author":"N Yoshimura","year":"1989","unstructured":"Yoshimura N, Oka T, Ohmori Y, Aikawa I. Effects of Recombinant human erythropoietin on the anaemia of renal transplant recipients with chronic rejection. Transplantation. 1989;48(3):527\u20139.","journal-title":"Transplantation"},{"issue":"7","key":"4115_CR247","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/j.1600-6143.2010.03142.x","volume":"10","author":"F Martinez","year":"2010","unstructured":"Martinez F, Kamar N, Pallet N, et al. High dose Epoetin beta in the first weeks following renal transplantation and delayed graft function: results of the Neo-PDGF study. Am J Transpl. 2010;10(7):1695\u2013700.","journal-title":"Am J Transpl"},{"key":"4115_CR248","doi-asserted-by":"crossref","unstructured":"Nakamura N, Aso S, Nakagawa C, Tachibana M, Fujikawa A, Tsubouchi K, et al. Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Therapy for Anemia in Renal Transplantation Patients by Prior Erythropoiesis Stimulating Agent Use. Transplantation Proceedings. 2023;55(4):829\u2013\u200931.","DOI":"10.1016\/j.transproceed.2023.03.062"},{"issue":"8","key":"4115_CR249","doi-asserted-by":"publisher","first-page":"100681","DOI":"10.1016\/j.xkme.2023.100681","volume":"5","author":"M Bonomini","year":"2023","unstructured":"Bonomini M, Di Liberato L, Sirolli V. Treatment options for Anemia in kidney transplant patients: A review. Kidney Med. 2023;5(8):100681.","journal-title":"Kidney Med"},{"issue":"3","key":"4115_CR250","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.transproceed.2022.02.004","volume":"54","author":"K Miki","year":"2022","unstructured":"Miki K, Nakamura Y, Yokoyama T, Kamiyama M, Ishii Y. Therapeutic effect of Roxadustat on patients with posttransplant Anemia. Transpl Proc. 2022;54(3):671\u20137.","journal-title":"Transpl Proc"},{"issue":"11","key":"4115_CR251","doi-asserted-by":"publisher","first-page":"11859","DOI":"10.21037\/apm-21-2916","volume":"10","author":"J Li","year":"2021","unstructured":"Li J, Ma K, Wang L, Qi H, Lv J, Rao Y, et al. Efficacy and safety of Roxadustat in the treatment of renal allograft anemia patients: a case series. Annals Palliat Med. 2021;10(11):11859\u201367. https:\/\/doi.org\/10.21037\/apm-21-2916.","journal-title":"Annals Palliat Med"},{"key":"4115_CR252","doi-asserted-by":"publisher","unstructured":"Naganuma Toshihide Experience with the Use of a Novel Agent. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, for Posttransplant Anemia in Renal Transplant Recipients: A Case Report Transplantation Proceedings 2022 54(2):544\u2013548. https:\/\/doi.org\/10.1016\/j.transproceed.2021.10.022","DOI":"10.1016\/j.transproceed.2021.10.022"},{"key":"4115_CR253","doi-asserted-by":"publisher","unstructured":"Li Hui Beneficial effect of roxadustat on. Early posttransplant anemia and iron utilization in kidney transplant recipients: a retrospective comparative cohort study. Annals Translational Med 2022 10(24):1360\u20131360, https:\/\/doi.org\/10.21037\/atm-22-5897","DOI":"10.21037\/atm-22-5897"},{"key":"4115_CR254","unstructured":"World Health Organisation. WHO recommendations on antenatal care for a positive pregnancy experience. 2016. Available at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/250796\/9789241549912-eng.pdf;jsessionid=F51CF06F12EAF86C6AC57079A965078A?sequence=1 (accessed December 2024)."},{"key":"4115_CR255","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1365-2141.2011.09012.x","volume":"156","author":"S Pavord","year":"2012","unstructured":"Pavord S, Myers B, Robinson S, et al. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2012;156:588\u2013600.","journal-title":"Br J Haematol"},{"key":"4115_CR256","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0301-2115(95)02538-3","volume":"69","author":"AK al-Momen","year":"1996","unstructured":"al-Momen AK, al-Meshari A, al-Nuaim L, et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1996;69:121\u20134.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"4115_CR257","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/01.AOG.0000185260.82466.b4","volume":"106","author":"RA Al","year":"2005","unstructured":"Al RA, Unlubilgin E, Kandemir O, et al. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol. 2005;106:1335\u201340.","journal-title":"Obstet Gynecol"},{"key":"4115_CR258","first-page":"78","volume":"138","author":"A Kriplani","year":"2013","unstructured":"Kriplani A, Mahey R, Dash BB, et al. Intravenous iron sucrose therapy for moderate to severe anaemia in pregnancy. Indian J Med Res. 2013;138:78\u201382.","journal-title":"Indian J Med Res"},{"key":"4115_CR259","first-page":"193","volume":"25","author":"N Tariq","year":"2015","unstructured":"Tariq N, Ayub R, Khan WU, et al. Parenteral iron therapy in the treatment of iron deficiency anemia during pregnancy: a randomized controlled trial. J Coll Physicians Surg Pak. 2015;25:193\u20137.","journal-title":"J Coll Physicians Surg Pak"},{"key":"4115_CR260","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1136\/bmj.310.6978.489","volume":"310","author":"P Steer","year":"1995","unstructured":"Steer P, Alam MA, Wadsworth J, et al. Relation between maternal haemoglobin concentration and birth weight in different ethnic groups. BMJ. 1995;310:489\u201391.","journal-title":"BMJ"},{"key":"4115_CR261","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.ackd.2020.06.001","volume":"27","author":"AL Oliverio","year":"2020","unstructured":"Oliverio AL, Hladunewich MA. End-stage kidney disease and dialysis in pregnancy. Adv Chronic Kidney Dis. 2020;27:477\u201385. https:\/\/doi.org\/10.1053\/j.ackd.2020.06.001.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"8","key":"4115_CR262","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/OGX.0b013e3182a2d51c","volume":"68","author":"L Sienas","year":"2013","unstructured":"Sienas L, Wong T, Collins R, Smith J. Contemporary uses of erythropoietin in pregnancy: a literature review. Obstet Gynecol Surv. 2013;68(8):594\u2013602.","journal-title":"Obstet Gynecol Surv"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04115-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04115-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04115-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T22:03:11Z","timestamp":1744840991000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04115-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":262,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4115"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04115-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"193"}}